Nabil S. Andrawis

Internal Medicine

5631 Burke Centre Pkwy Ste A
Burke, VA 22015

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 5 publications

Aprocitentan for Blood Pressure Reduction in Black Patients.

Aprocitentan for Blood Pressure Reduction in Black Patients.

Journal: Hypertension (Dallas, Tex. : 1979)

Published: January 22, 2025

Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Author Correction: The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Journal: Nature medicine

Published: March 04, 2024

Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.

Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.

Journal: Diabetes, obesity & metabolism

Published: February 23, 2023

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial.

Journal: Nature medicine

Published: January 29, 2023

Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US.

Characteristics, management, and blood pressure control in patients with apparent resistant hypertension in the US.

Journal: Heliyon

Published: June 28, 2022

Showing 1-5 of 5

Last Updated: 09/26/2026